{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T10:37:28Z","timestamp":1747219048350,"version":"3.40.5"},"reference-count":72,"publisher":"Publishing Center Science and Practice","issue":"4","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BSP"],"abstract":"<jats:p>Purpose: using the example of our own clinical case to demonstrate the complexity of diagnostics at the outpatient stage of multiple myeloma, occurring against the background of comorbid pathologies and the new coronavirus disease 2019 associated with pneumonia. Materials and methods. Based on the data from the medical record of an outpatient patient, a diagnostic search in a 70-year-old patient with pain in the thoracic spine was analyzed. Results. The article describes a case of multiple myeloma proceeding under the guise of thoracalgia against the background of concomitant cardiovascular diseases, as well as comorbid pathologies. During the examination, computed tomography of the chest organs for the addition of infectious complications in the form of pneumonia (COVID-19) showed characteristic bone changes in multiple myeloma. In all bones of the chest at the level of the thoracic spine, multiple solid formations with irregular contours were found, causing destruction of bone tissue. Biochemical examination revealed anemia, hypercalcemia, hypercreatininemia. In the patient, the M-gradient (Bens-Jones protein) in the urine is represented by kappa light chains in the monoclonal component and free kappa light chains. According to the results of the study, the clinical diagnosis was established: multiple myeloma stage III B, first diagnosed, with lesions of the ribs and thoracic spine. Conclusion. Diagnosis of multiple myeloma is a difficult task for a practicing therapist due to the lack of alertness and heterogeneity of the clinical picture. In elderly people, the diagnosis of multiple myeloma is much more difficult due to the presence of a significant number of comorbid pathologies.<\/jats:p>","DOI":"10.33619\/2414-2948\/65\/22","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:47:31Z","timestamp":1618444051000},"page":"186-211","source":"Crossref","is-referenced-by-count":0,"title":["Multiple Myeloma and Comorbidal Diseases in the Practice of a Doctor: A Literature Review and a Clinical Case Description"],"prefix":"10.33619","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-9279","authenticated-orcid":false,"given":"I.","family":"Murkamilov","sequence":"first","affiliation":[{"name":"Kyrgyz State Medical Academy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-039X","authenticated-orcid":false,"given":"K.","family":"Aitbaev","sequence":"additional","affiliation":[{"name":"Scientific Research Institute of Molecular Biology and Medicine, Bishkek"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3007-8127","authenticated-orcid":false,"given":"I.","family":"Kudaibergenova","sequence":"additional","affiliation":[{"name":"Kyrgyz State Medical Academy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2682-4417","authenticated-orcid":false,"given":"V.","family":"Fomin","sequence":"additional","affiliation":[{"name":"The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7653-0433","authenticated-orcid":false,"given":"Zh.","family":"Murkamilova","sequence":"additional","affiliation":[{"name":"Kyrgyz-Russian Slavic University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0632-6653","authenticated-orcid":false,"given":"F.","family":"Yusupov","sequence":"additional","affiliation":[{"name":"Osh State University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19222","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Mendeleeva, L. P., Votyakova, O. M., Rekhtina, I. G., Osmanov, E. A., Poddubnaya, I. V., Grivtsova, L. Yu., Falaleeva, N. A., Baikov, V. V., Kovrigina, A. M., Nevolskikh, A. A., Ivanov, S. A., Khailova, Zh. V., & Gevorkyan, T. G. (2020). Clinical guidelines. Multiple myeloma. Association of Oncologists of Russia. National Hematological Society. Russian Professional Society of Oncohematologists.","DOI":"10.26442\/18151434.2020.4.200457"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Becker, N. (2011). Epidemiology of multiple myeloma. Multiple myeloma, 25-35. https:\/\/doi.org\/10.1007\/978-3-540-85772-3_2","DOI":"10.1007\/978-3-540-85772-3_2"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Bence Jones, H. (1847). Papers on Chemical Pathology; The Lancet, 50(1247), 88-92. https:\/\/doi.org\/10.1016\/S0140-6736(02)86528-X","DOI":"10.1016\/s0140-6736(02)86528-x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Rustizky, J. V. (1873). Multiples myelom. Deutsche Zeitschrift f\u00fcr Chirurgie, 3(1), 162-172. https:\/\/doi.org\/10.1007\/BF02911073","DOI":"10.1007\/bf02911073"},{"key":"ref4","unstructured":"Kahler, O. (1889). Zur Symptomalogii des multiple Myleoms: Beobachtung von Albomosurie. Prager Medinische Wochenschrift, 14. 45."},{"key":"ref5","unstructured":"\u0421\u0435\u043c\u043e\u0447\u043a\u0438\u043d \u0421. \u0412. \u041c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u043c\u0438\u0435\u043b\u043e\u043c\u0430 (\u0438\u043d\u0442\u0435\u0440\u0432\u044c\u044e \u043f\u0440\u043e\u0432\u043e\u0434\u0438\u043b \u0434-\u0440 \u043c\u0435\u0434. \u043d\u0430\u0443\u043a, \u043f\u0440\u043e\u0444\u0435\u0441\u0441\u043e\u0440 \u0415. \u0410. \u041e\u0441\u043c\u0430\u043d\u043e\u0432) \/\/ \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0430\u044f \u043e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2020. \u0422. 13. \u21161. \u0421. 1-24."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Bolotin, S. G., Zenina, M. S., Pristupa, A. S., \u2026 Solovieva, A. V. (2020). Clinical and Epidemiological Characteristics of Multiple Myeloma in the Ryazan Region. Nauka Molodykh (Eruditio Juvenium), 8(4), 541-548. https:\/\/doi.org\/10.23888\/HMJ202084541-548","DOI":"10.23888\/hmj202084541-548"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Jemel, A. (2008). Cancer statistics 2008. Ca Cancer J. Clin., 58, 71-96.","DOI":"10.3322\/CA.2007.0010"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Cid Ruzafa, J., Merinopoulou, E., Baggaley, R. F., Leighton, P., Werther, W., Felici, D., & Cox, A. (2016). Patient population with multiple myeloma and transitions across different lines of therapy in the USA: an epidemiologic model. Pharmacoepidemiology and drug safety, 25(8), 871-879. https:\/\/doi.org\/10.1002\/pds.3927","DOI":"10.1002\/pds.3927"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Rosenberg, P. S., Barker, K. A., & Anderson, W. F. (2015). Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity. Blood, The Journal of the American Society of Hematology, 125(2), 410-412. https:\/\/doi.org\/10.1182\/blood-2014-10-609461","DOI":"10.1182\/blood-2014-10-609461"},{"key":"ref10","unstructured":"\u0424\u0438\u043b\u044c\u0447\u0435\u043d\u043a\u043e\u0432 \u0410. \u0410. \u0410\u0434\u0438\u043f\u043e\u0446\u0438\u0442\u044b \u043a\u043e\u0441\u0442\u043d\u043e\u0433\u043e \u043c\u043e\u0437\u0433\u0430 \u043f\u0440\u0438 \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u0435 \/\/ \u041e\u043d\u043a\u043e\u0433\u0435\u043c\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u044f. 2019. \u0422. 14. \u21161. \u0421. 60-75."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Harousseau, J. L., & Dreyling, M. (2010). Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 21, v155-v157. https:\/\/doi.org\/10.1093\/annonc\/mdq178","DOI":"10.1093\/annonc\/mdq178"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Wang, S., Xu, L., Feng, J., Liu, Y., Liu, L., Wang, J., ... & Zhan, S. (2020). Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis. Frontiers in oncology, 9, 1513. https:\/\/doi.org\/10.3389\/fonc.2019.01513","DOI":"10.3389\/fonc.2019.01513"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Skvortsova, N., Pospelova, T., Kovynev, I., Soldatova, G., \u2026 Nechunaeva, I. (2018). Epidemiology of Multiple Myeloma in Novosibirsk (Siberian Federal District). Clinical Oncohematology, 12(1), 86-94. https:\/\/doi.org\/10.21320\/2500-2139-2019-12-1-86-94","DOI":"10.21320\/2500-2139-2019-12-1-86-94"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Vinogradova, O. Y., Ptushkin, V. V., Chernikov, M. V., Kochkareva, Y. B., & Zherebtsova, V. A. (2019). Epidemiology of multiple myeloma in city Moscow. Terapevticheskii Arkhiv, 91(7), 83-92. https:\/\/doi.org\/10.26442\/00403660.2019.07.000305","DOI":"10.26442\/00403660.2019.07.000305"},{"key":"ref15","unstructured":"Kucherenko, T. Yu. (2017). Multiple myeloma in the Amur region. Youth of the XXI century: a step into the future, 743-744."},{"key":"ref16","unstructured":"\u041c\u0438\u0445\u0430\u043b\u0435\u0432 \u041c. \u0410., \u041a\u0443\u0437\u043d\u0435\u0446\u043e\u0432\u0430 \u0415. \u042e., \u0421\u044b\u0440\u0446\u0435\u0432\u0430 \u0415. \u0411., \u0421\u043e\u043a\u043e\u043b\u043e\u0432\u0430-\u041f\u043e\u043f\u043e\u0432\u0430 \u0422. \u0410. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0441\u043b\u0443\u0447\u0430\u0439 \u0440\u0435\u0434\u043a\u043e\u0433\u043e \u0441\u043e\u0447\u0435\u0442\u0430\u043d\u0438\u044f \u043c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u043e\u0439 \u043c\u0438\u0435\u043b\u043e\u043c\u044b \u0438 \u043c\u0438\u0435\u043b\u043e\u043f\u0440\u043e\u043b\u0438\u0444\u0435\u0440\u0430\u0442\u0438\u0432\u043d\u043e\u0433\u043e \u0437\u0430\u0431\u043e\u043b\u0435\u0432\u0430\u043d\u0438\u044f \/\/ \u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u044b\u0435 \u043f\u0440\u043e\u0431\u043b\u0435\u043c\u044b \u043d\u0430\u0443\u043a\u0438 \u0438 \u043e\u0431\u0440\u0430\u0437\u043e\u0432\u0430\u043d\u0438\u044f. 2016. \u21165. \u0421. 79-87."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Vasilev V. I., Gorodetskiy V. R., Sedyshev S. K., Probatova N. A., Pavlovskaya A. I., Varlamova M. Yu., Palshina S. G., Logunov A. L., Logvinenko O.A., Sokol E. V., Nasonov E. L., Vasilyev V. I., Gorodetsky V. R., Sedyshev S. K., Probatova N. A., Pavlovskaya A. I., Varlamova M. Yu., Palshina S. G., Logunov A. L., Logvinenko O., Sokol E. V., Nasonov E. L. (2010). Clinical manifestations of vasculitis at the onset of multiple myeloma. Rheumatology Science and Practice, 48(1), 81-87. https:\/\/doi.org\/10.14412\/1995-4484-2010-1410","DOI":"10.14412\/1995-4484-2010-1410"},{"key":"ref18","unstructured":"Nevozhaj, A. V., & Tatarkina, N. D. (2009). Clinical picture of patients multiple myeloma in Primorye territory. Siberian Medical Journal (Irkutsk), 85(2), 85-88."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Smirnov, A. V., Afanasyev, B. V., Poddubnaya, I. V., Dobronravov, V. A., Khrabrova, M. S., Zakharova, E. V., Nikitin, E. A., Kozlovskaya, L. V., Bobkova, I. N., Rameev, V. V., Batyushin, M. M., Moiseev, Ch. S., Darskaya, E. I., Pirogova, O. V., Mendeleeva, L. P., & Biryukova, L. S. (2020). Monoclonal Gammopathy of Renal Significance: Consensus of Hematologists and Nephrologists of Russia on the Establishment of Nosology, Diagnostic Approach and Rationale for Clone Specific Treatment. Russian Archives of Internal Medicine, 10(2), 102-118. https:\/\/doi.org\/10.20514\/2226-6704-2020-10-2-102-118","DOI":"10.20514\/2226-6704-2020-0-2-102-118"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Bulanov, A. Yu., & Simarova I. B. (2018). Hemostasiological portrait of multiple myeloma. Clinical Nephrology, (2), 23-25. https:\/\/doi.org\/10.18565\/nephrology.2018.2.23-25","DOI":"10.18565\/nephrology.2018.2.23-25"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Misyurina, E. N., & Misyurin, A. V. (2018). Genetic abnormalities in patients with multiple myeloma. Clinical Nephrology, (2), 11-14. https:\/\/doi.org\/10.18565\/nephrology.2018.2.11-14","DOI":"10.18565\/nephrology.2018.2.11-14"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Semochkin, S. V. (2018). Diagnosis and principles of therapy of multiple myeloma. Clinical Nephrology, (2), 15-22. https:\/\/doi.org\/10.18565\/nephrology.2018.2.15-22","DOI":"10.18565\/nephrology.2018.2.15-22"},{"key":"ref23","unstructured":"Murkamilov, I., Sabirov, I., Fomin, V., Murkamilova, Zh., & Yusupov, F. (2021). Electrolytic imbalance and heart arrhythmies in chronic kidney disease. Scientific heritage, 60-2(60), 55-70. https:\/\/doi.org\/10.24412\/9215-0365-2021-60-2-55-70"},{"key":"ref24","unstructured":"Shatokhin, Y. V., & Bakulina, E. S. (2012). Features of clinical course of multiple myelomas at long-term polychemotherapy. Journal of Siberian Medical Sciences, 5."},{"key":"ref25","unstructured":"Mironova, D. \u200aA., Koroleva, L. Yu., Samoilova, O. S., & Mironova, N. V. (2020). Venous thromboembolic complications in oncohematology (brief review). Meditsinskii almanakh, 62(1), 20-26."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Leebeek, F. W. (2016). Update of thrombosis in multiple myeloma. Thrombosis research, 140, S76-S80. https:\/\/doi.org\/10.1016\/s0049-3848(16)30103-7","DOI":"10.1016\/s0049-3848(16)30103-7"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Carrier, M., Le Gal, G., Tay, J., Wu, C., & Lee, A. Y. (2011). Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta\u2010analysis. Journal of Thrombosis and Haemostasis, 9(4), 653-663. https:\/\/doi.org\/10.1111\/j.1538-7836.2011.04215.x","DOI":"10.1111\/j.1538-7836.2011.04215.x"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Smirnova, O. V., Manchuk, V. T., & Agilova, Y. N. (2015). Clinical and Immunological Features of Infectious Complications in Patients with Multiple Myeloma. Annals of the Russian Academy of Medical Sciences, 70(5), 534-540. https:\/\/doi.org\/10.15690\/vramn.v70.i5.1439","DOI":"10.15690\/vramn.v70.i5.1439"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Novikova, A. A., Klyasova, G. A., Gribanova, E. O., Okhmat, V. A., Ryzhko, V. V., & Savchenko, V. G. (2018). Infectious complications in patients with multiple myeloma on first chemotherapy cycle. Oncohematology, 13(3), 63-75. https:\/\/doi.org\/10.17650\/1818-8346-2018-13-3-63-75","DOI":"10.17650\/1818-8346-2018-13-3-63-75"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Bolli, N., Martinelli, G., & Cerchione, C. (2020). The molecular pathogenesis of multiple myeloma. Hematology Reports, 12(3). 9054-9054. https:\/\/doi.org\/10.4081\/hr.2020.9054","DOI":"10.4081\/hr.2020.9054"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., ... & Ajebo, G. H. (2021). Epidemiology, Staging, and Management of Multiple Myeloma. Medical Sciences, 9(1), 3. https:\/\/doi.org\/10.3390\/medsci9010003","DOI":"10.3390\/medsci9010003"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Kaweme, N. M., Changwe, G. J., & Zhou, F. (2021). Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects. Frontiers in Medicine, 8, 180. https:\/\/doi.org\/10.3389\/fmed.2021.612696","DOI":"10.3389\/fmed.2021.612696"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Rekhtina, I. G., & Mendeleeva, L. P. (2017). Current approaches to treating of patients with multiple myeloma with renal failure: Questions and proofs. Terapevticheskii arkhiv, 89(7). 112-117. https:\/\/doi.org\/10.17116\/terarkh2017897112-117","DOI":"10.17116\/terarkh2017897112-117"},{"key":"ref34","unstructured":"Bessmeltsev, S. S. (2013). Multiple myeloma (management of newly diagnosed patients): literature review and our on data. Part II. Clinical hematology oncology, 6(4). 379-414."},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Samoylovich, M. P., Griazeva, I. V., Mazing, A. V., Lapin, S. V., & Klimovich, V. B. (2016). Immunometric Assay to Determine Free Light Chain Concentrations of Human Immunoglobulins. Medical Immunology (Russia), 18(4), 385-394. https:\/\/doi.org\/10.15789\/1563-0625-2016-4-385-394","DOI":"10.15789\/1563-0625-2016-4-385-394"},{"key":"ref36","unstructured":"Votyakova, O. M., Lyubimova, N. V., Turko, T. A., Yakimovich, O. Yu., & Kogarko, I. N. (2010). Clinical implication of immunoglobulin free light chains study in patients with multiple myeloma. Bulletin of the Russian Oncology Center N.N. Blokhin RAMS, (4:21). 16-22."},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Golenkov, A. K., Trifonova, E. V., Kataeva, E. V., Mitina, T. A., Vusotskaya, L. L., Chernykh, Yu. B., Klinushkina, E. F., Belousov, K. A., Kogarko, I. N., Zakharov, S. G., Karaulov, A. V., Kogarko, B. S., & Maryina, S. A. (2019). Assay of immunoglobulin free light chains in the serum for evaluating chemotherapy efficacy in patients suffering from multiple myeloma with intact measurable paraprotein. Russian journal of hematology and transfusiology, 64(1), 7-15. https:\/\/doi.org\/10.35754\/0234-5730-2019-64-1-7-15","DOI":"10.35754\/0234-5730-2019-64-1-7-15"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Durie, B. G., Harousseau, J. L., Miguel, J. S., Blade, J., Barlogie, B., Anderson, K., ... & Rajkumar, S. V. (2006). International uniform response criteria for multiple myeloma. Leukemia, 20(9), 1467-1473. https:\/\/doi.org\/10.1038\/sj.leu.2404284","DOI":"10.1038\/sj.leu.2404284"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Mart\u00edn-Nares, E., Saavedra-Gonz\u00e1lez, V., Fagundo-Sierra, R., Santinelli-N\u00fa\u00f1ez, B. E., Romero-Maceda, T., Calder\u00f3n-Vasquez, K., & Hernandez-Molina, G. (2021). Serum immunoglobulin free light chains and their association with clinical phenotypes, serology and activity in patients with IgG4-related disease. Scientific Reports, 11(1), 1-11. https:\/\/doi.org\/10.1038\/s41598-021-81321-5","DOI":"10.1038\/s41598-021-81321-5"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Hutchison, C.A., Blad\u00e9, J., Cockwell, P., Cook, M., Drayson, M., Fermand, J. P., & Winearls, C. (2012). Novel approaches for reducing free light chains in patients with myeloma kidney. Nature Reviews Nephrology, 8(4), 234-243. https:\/\/doi.org\/10.1038\/nrneph.2012.14","DOI":"10.1038\/nrneph.2012.14"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Albayrak, M., Celebi, H., Albayrak, A., Sayilir, A., Yesil, Y., Balcik, O. S., ... & Celik, T. (2012). Elevated serum angiotensin converting enzyme levels as a reflection of bone marrow renin\u2013angiotensin system activation in multiple myeloma. Journal of the Renin-Angiotensin-Aldosterone System, 13(2), 259-264. https:\/\/doi.org\/10.1177\/1470320312437070","DOI":"10.1177\/1470320312437070"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Zamagni, E. (2021). Introduction: Management of Bone Disease and Kidney Failure in Multiple Myeloma. Management of Bone Disease and Kidney Failure in Multiple Myeloma. Cham., Springer, 1-5. https:\/\/doi.org\/10.1007\/978-3-030-63662-3_1","DOI":"10.1007\/978-3-030-63662-3_1"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Israelyan, E. R., Golovataya, C. S., Bondarenko, O. K., Nayda, A. V., & Pudeeva, A. K. (2019). Onset of multiple myeloma with rheumatic polymyalgia. Medical Herald of the South of Russia, 10(4), 98-104. https:\/\/doi.org\/10.21886\/2219-8075-2019-10-4-98-104","DOI":"10.21886\/2219-8075-2019-10-4-98-104"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Maneix, L., Sweeney, M. A., Lee, S., Iakova, P., Moree, S. E., Sahin, E., ... & Catic, A. (2021). The Mitochondrial Protease LonP1 Promotes Proteasome Inhibitor Resistance in Multiple Myeloma. Cancers, 13(4), 843. https:\/\/doi.org\/10.3390\/cancers13040843","DOI":"10.3390\/cancers13040843"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Barker, H. F., Ball, J., Drew, M., Hamilton, M. S., & Franklin, I. M. (1992). The role of adhesion molecules in multiple myeloma. Leukemia & lymphoma, 8(3), 189-196. https:\/\/doi.org\/10.3109\/10428199209054904","DOI":"10.3109\/10428199209054904"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Zhang, Y., Zhang, C., Zhou, J., Zhang, J., Chen, X., Chen, J., ... & Li, C. (2021). Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement. Frontiers in immunology, 12, 236. https:\/\/doi.org\/10.3389\/fimmu.2021.552429","DOI":"10.3389\/fimmu.2021.552429"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Giuliani, N., Costa, F., & Marchica, V. (2021). The Pathophysiology of Myeloma Bone Disease: Role of Osteoblasts and Osteocytes. Management of Bone Disease and Kidney Failure in Multiple Myeloma. Cham., Springer, 37-51. https:\/\/doi.org\/10.1007\/978-3-030-63662-3_3","DOI":"10.1007\/978-3-030-63662-3_3"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Moonga, B. S., Adebanjo, O. A., Wang, H. J., Li, S., Wu, X. B., Troen, B., ... & Zaidi, M. (2002). Differential effects of interleukin-6 receptor activation on intracellular signaling and bone resorption by isolated rat osteoclasts. Journal of Endocrinology, 173(3), 395-405. https:\/\/doi.org\/10.1677\/joe.0.1730395","DOI":"10.1677\/joe.0.1730395"},{"key":"ref49","unstructured":"Heltser, B. I., Zhilkova, N. N., Anufrieva, N. D., Kochetkova, E. A. (2011). Bone lesions in case of multiple myeloma. Pacific Medical Journal, (3), 11-16."},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Andrews, R. E., Chantry, A. D., & Ashcroft, A. J. The Pathophysiology of Myeloma Bone Disease: Bone Remodelling and the Role of Osteoclasts. Management of Bone Disease and Kidney Failure in Multiple Myeloma. Cham., Springer, 7-36. https:\/\/doi.org\/10.1007\/978-3-030-63662-3_2","DOI":"10.1007\/978-3-030-63662-3_2"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Wiszniak, S., & Schwarz, Q. (2021). Exploring the Intracrine Functions of VEGF-A. Biomolecules, 11(1), 128. https:\/\/doi.org\/10.3390\/biom11010128","DOI":"10.3390\/biom11010128"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Takasu, M., Tanitame, K., Baba, Y., Akiyama, Y., Tamura, T., Kondo, S., ... & Awai, K. (2021). Does chemical shift imaging offer a biomarker for the diagnosis and assessment of disease severity in multiple myeloma? A cross-sectional study. Medicine, 100(6). https:\/\/doi.org\/10.1097\/MD.0000000000024358","DOI":"10.1097\/md.0000000000024358"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Lin, Z. S., Qin, A. B., Wang, S. X., Yu, X. J., Dong, B., Xiong, Z. Y., ... & Zhao, M. H. A non-invasive differential diagnostic model for light chain cast nephropathy in newly diagnosed multiple myeloma patients with renal involvement: a multicenter study. Journal of nephrology, 1-9. https:\/\/doi.org\/10.1007\/s40620-020-00926-7","DOI":"10.1007\/s40620-020-00926-7"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Tabata, R., Yasumizu, R., Tabata, C., & Kojima, M. (2013). CD20-negative low-grade B cell lymphoma showing immunophenotypic and genotypic features resembling plasma cell myeloma. Pathology-Research and Practice, 209(7), 459-462. https:\/\/doi.org\/10.1016\/j.prp.2013.04.007","DOI":"10.1016\/j.prp.2013.04.007"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Mykytiv, V., Alwaheed, A., & Hashim, N. A. M. (2019). Double CD38\u2212\/CD138\u2212 negative multiple myeloma. Hematology\/oncology and stem cell therapy, 12(1), 64-66. https:\/\/doi.org\/10.1016\/j.hemonc.2017.08.003","DOI":"10.1016\/j.hemonc.2017.08.003"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Stege, C. A. M., Nasserinejad, K., Klein, S. K., Timmers, G.-J., Hoogendoorn, M., Ypma, P. F., \u2026 Zweegman, S. (2021). Improving the identification of frail elderly newly diagnosed multiple myeloma patients. Leukemia, 1-5. https:\/\/doi.org\/10.1038\/s41375-021-01162-z","DOI":"10.1038\/s41375-021-01162-z"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Yavorkovsky, L. L. (2021). Smoldering multiple myeloma 40 years later: a story of unintended disease. Expert Review of Hematology. https:\/\/doi.org\/10.1080\/17474086.2021.1875815","DOI":"10.1080\/17474086.2021.1875815"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Terpos, E., Zamagni, E., Lentzsch, S., Drake, M. T., Garc\u00eda-Sanz, R., Abildgaard, N., ... & Myeloma Working Group. (2021). Treatment of multiple myeloma-related bone disease: Recommendations from the Bone Working Group of the International Myeloma Working Group. The Lancet Oncology. https:\/\/doi.org\/10.1016\/S1470-2045(20)30559-3","DOI":"10.1016\/s1470-2045(20)30559-3"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Garcia-Gomez, A., Li, T., de la Calle-Fabregat, C., Rodr\u00edguez-Ubreva, J., Ciudad, L., Catal\u00e0-Moll, F., ... & Ballestar, E. (2021). Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. Nature Communications, 12(1), 1-15. https:\/\/doi.org\/10.1038\/s41467-020-20715-x","DOI":"10.1038\/s41467-020-20715-x"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Scott, K., Hayden, P. J., Will, A., Wheatley, K., & Coyne, I. (2016). Bortezomib for the treatment of multiple myeloma. Cochrane Database of Systematic Reviews, (4). https:\/\/doi.org\/10.1002\/14651858.CD010816.pub2","DOI":"10.1002\/14651858.cd010816"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Moreau, P., Sonneveld, P., Boccadoro, M., Cook, G., Mateos, M. V., Nahi, H., ... & Einsele, H. (2019). Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. Haematologica, 104(12), 2358. https:\/\/doi.org\/10.3324\/haematol.2019.224204","DOI":"10.3324\/haematol.2019.224204"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Zuo, X., & Liu, D. Progress in the application of minimal residual disease detection in multiple myeloma. Journal of Hematopathology, 1-11. https:\/\/doi.org\/10.1007\/s12308-020-00436-2","DOI":"10.1007\/s12308-020-00436-2"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"O\u2019Connor, M. H., Madugula, K., & Smith, M. (2020). Chimeric Antigen Receptor T Cells: Clinical Applications, Advances and Challenges. Advanced Concepts in Human Immunology: Prospects for Disease Control. Cham., Springer, 319-333. https:\/\/doi.org\/10.1007\/978-3-030-33946-3_7","DOI":"10.1007\/978-3-030-33946-3_7"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Pavlova, V. Yu., & Livadnyi E. S. (2021). CAR-T Technology and New Opportunities for Tumor Treatment. Clinical oncohematology, 14(1), 149-156. https:\/\/doi.org\/10.21320\/2500-2139-2021-14-1-149-156","DOI":"10.21320\/2500-2139-2021-14-1-149-156"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Expert Council resolution on the specifics of multiple myeloma therapy during COVID-19 pandemic (2020). Oncohematology, 15(2), 108-112. https:\/\/doi.org\/10.17650\/1818-8346-2020-15-2-108-112","DOI":"10.17650\/1818-8346-2020-15-2-108-112"},{"key":"ref66","unstructured":"Sabirov, I. S., Murkamilov, I. T., Fomin, V. V. (2021). The functional state of the liver and pancreas in COVID-19: the view of the therapist. Scientific Heritage, (50-2 (50)), 35-41."},{"key":"ref67","unstructured":"Sabirov, I. S., Murkamilov, I. T., Fomin, V. V. (2020). Clinical and pathogenetic aspects of damage to the cardiovascular system in a new coronavirus infection (COVID-19). Scientific Heritage, (53-1 (53)), 10-20."},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Candales, A., Mathur, P., & Xu, J. (2021). Managing multiple myeloma during COVID-19: an ongoing saga. https:\/\/doi.org\/10.1080\/00325481.2021.1885882","DOI":"10.1080\/00325481.2021.1885882"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Camilleri, M., Sive, J., Wilson, W., Pang, G., Jenner, R., Phillips, E., ... & Yong, K. (2021). COVID\u201019 and myeloma clinical research - experience from the CARDAMON clinical trial. British Journal of Haematology, 192(1), e14. https:\/\/doi.org\/10.1111\/bjh.17168","DOI":"10.1111\/bjh.17168"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Gavriatopoulou, M., Ntanasis-Stathopoulos, I., Korompoki, E., Terpos, E., & Dimopoulos, M. A. (2021). SARS-CoV-2 Vaccines in Patients With Multiple Myeloma. HemaSphere, 5(3), https:\/\/doi.org\/10.1097\/HS9.0000000000000547","DOI":"10.1097\/hs9.0000000000000547"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Tang, A. S. O., Leong, T. S., Chew, L. P., & Chua, H. H. (2021). Successful Non-surgical Treatment of an Acute Calculous Cholecystitis in a Myeloma Patient with Covid-19: Case Report. SN comprehensive clinical medicine, 3(2), 666-669. https:\/\/doi.org\/10.1007\/s42399-021-00785-8","DOI":"10.1007\/s42399-021-00785-8"}],"container-title":["Bulletin of Science and Practice"],"original-title":["\u041c\u043d\u043e\u0436\u0435\u0441\u0442\u0432\u0435\u043d\u043d\u0430\u044f \u043c\u0438\u0435\u043b\u043e\u043c\u0430 \u0438 \u043a\u043e\u043c\u043e\u0440\u0431\u0438\u0434\u043d\u044b\u0435 \u043f\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438 \u0432 \u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0435 \u0432\u0440\u0430\u0447\u0430: \u043b\u0438\u0442\u0435\u0440\u0430\u0442\u0443\u0440\u043d\u044b\u0439 \u043e\u0431\u0437\u043e\u0440 \u0438 \u043e\u043f\u0438\u0441\u0430\u043d\u0438\u0435 \u043a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u0441\u043b\u0443\u0447\u0430\u044f"],"language":"ru","deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T16:22:38Z","timestamp":1667319758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.elibrary.ru\/item.asp?id=45658710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":72,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,4,15]]}},"URL":"https:\/\/doi.org\/10.33619\/2414-2948\/65\/22","relation":{},"ISSN":["2414-2948"],"issn-type":[{"type":"electronic","value":"2414-2948"}],"subject":[],"published":{"date-parts":[[2021,4,15]]}}}